Actively Recruiting
Plasmodium Immunotherapy for Advanced Cancers
Led by CAS Lamvac Biotech Co., Ltd. · Updated on 2024-02-20
20
Participants Needed
1
Research Sites
453 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety of Plasmodium immunotherapy and preliminarily evaluate the effectiveness of Plasmodium immunotherapy for advanced cancers.The treatment will last 3-6 months from the day of successful infection and will be terminated by antimalarial drugs.
CONDITIONS
Official Title
Plasmodium Immunotherapy for Advanced Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 70 years, any gender
- Advanced cancer confirmed by tissue and imaging with measurable tumor lesions, including colon, breast, liver, lung, gastric cancer, sarcoma, and other solid tumors except nasopharyngeal carcinoma, lymphatic cancer, cervical cancer, and melanoma
- At least 3 months since last chemotherapy or radiotherapy; at least 5 half-lives since last targeted drug therapy
- Patients who have not received or refuse surgery, radiotherapy, chemotherapy, or targeted therapy must meet all other criteria
- ECOG performance score of 0 or 1
- Expected survival of 6 months or more
- Platelet count ≥100×10^9/L, neutrophils ≥1.5×10^9/L, hemoglobin ≥100 g/L with no significant red blood cell abnormalities or anemia
- Peripheral immune cell counts near normal and normal heart, lung, liver, and kidney function; liver function classified as Child-Pugh A or B; creatinine ≤1.5 times upper limit of normal
- Willingness to comply with follow-up requirements
- Able to understand and sign informed consent
You will not qualify if you...
- Severe hemoglobin disease or severe G6PD deficiency
- History of spleen removal or enlarged spleen
- Drug addiction or alcohol dependence
- Newly diagnosed central nervous system metastasis (unless lesions have disappeared after treatment)
- Serious or uncontrolled systemic diseases including active infections, severe hypertension, unstable angina, heart failure class III or IV, severe arrhythmia, liver or kidney dysfunction, metabolic diseases, neurological or psychiatric disorders
- Receiving any other anti-tumor treatments concurrently
- Significantly reduced immune function below normal
- Severe lung function impairment or inability to leave bed, persistent shortness of breath at rest
- Severe cough or breathing difficulties affecting diet or cooperation
- Poor general condition deemed unable to tolerate immunotherapy
- Pregnant or breastfeeding women
- Women of childbearing age with positive pregnancy tests
- Any other condition making participation unsuitable according to investigator judgement
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Guangzhou Fuda Tumor Hospital
Guangzhou, Guangdong, China, 510000
Actively Recruiting
Research Team
L
Li Qin, M.D
CONTACT
S
Suyi Zhang, M.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here